Literature DB >> 9485211

Multiple sequences from downstream of the J kappa cluster can combine to recruit somatic hypermutation to a heterologous, upstream mutation domain.

N Klix1, C J Jolly, S L Davies, M Brüggemann, G T Williams, M S Neuberger.   

Abstract

Recruitment of somatic hypermutation to the Ig kappa locus has previously been shown to depend on the enhancer elements, Ei/MAR and E3'. Here we show that these elements are not sufficient to confer mutability. However, hypermutation is effectively targeted to a chimeric beta-globin/Ig kappa transgene whose 5' end is composed of the human beta-globin gene (promoter and first two exons) and whose 3' end consists of selected sequences derived from downstream of the J kappa cluster (Ei/MAR, C kappa + flank and E3'). Thus, multiple downstream Ig kappa sequences (all derived from 3' of the J kappa cluster) can combine to recruit mutation to a heterologous mutation domain. The location of this hypermutation domain is defined by the position of the transcription start site and this applies even if the Ig kappa Ei/MAR is positioned upstream of the promoter. Hotspots within the mutation domain are, however, defined by local DNA sequence as evidenced by a new hotspot being created within the beta-globin domain by a mutation within the transgene. We propose that multiple, moveable Ig kappa sequences (that are normally located downstream of the transcription start site) cooperate to bring a hypermutation priming factor to the transcription initiation complex; a mutation domain is thereby created downstream of the promoter but the local sequence defines the detailed pattern of mutation within that domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485211     DOI: 10.1002/(SICI)1521-4141(199801)28:01<317::AID-IMMU317>3.0.CO;2-S

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

Review 1.  The reverse transcriptase model of somatic hypermutation.

Authors:  E J Steele; R V Blanden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

Review 2.  Somatic immunoglobulin hypermutation.

Authors:  Marilyn Diaz; Paolo Casali
Journal:  Curr Opin Immunol       Date:  2002-04       Impact factor: 7.486

Review 3.  Somatic hypermutation in human B cell subsets.

Authors:  N S Longo; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  2001-12

4.  Genome-wide somatic hypermutation.

Authors:  Clifford L Wang; Ryan A Harper; Matthias Wabl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-29       Impact factor: 11.205

5.  Both DNA strands of antibody genes are hypermutation targets.

Authors:  C Milstein; M S Neuberger; R Staden
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

6.  The zebrafish IgH locus contains multiple transcriptional regulatory regions.

Authors:  N Danilova; H L Saunders; K K Ellestad; B G Magor
Journal:  Dev Comp Immunol       Date:  2010-11-11       Impact factor: 3.636

7.  A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression.

Authors:  Ai Kotani; Il-Mi Okazaki; Masamichi Muramatsu; Kazuo Kinoshita; Nasim A Begum; Toshiharu Nakajima; Hirohisa Saito; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

Review 8.  Antibody diversification: mutational mechanisms and oncogenesis.

Authors:  Darina Frieder; Mani Larijani; Ephraim Tang; Jahan-Yar Parsa; Wajiha Basit; Alberto Martin
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

9.  Transcriptional pausing and stalling causes multiple clustered mutations by human activation-induced deaminase.

Authors:  Chandrika Canugovi; Mala Samaranayake; Ashok S Bhagwat
Journal:  FASEB J       Date:  2008-09-04       Impact factor: 5.191

10.  A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation.

Authors:  Artem Blagodatski; Vera Batrak; Sabine Schmidl; Ulrike Schoetz; Randolph B Caldwell; Hiroshi Arakawa; Jean-Marie Buerstedde
Journal:  PLoS Genet       Date:  2009-01-09       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.